Following MTHMS + L treatment, the proportion of tumor-reactive gp70 tetramer-specific CD8+ T cells rose to a high level of ~4.5% (Supplementary Fig. 35, 36), indicating the induction of tumor-specific T-cell immunity. The gene discussed is EMB; the disease is neoplasm.